期刊文献+

美国儿科药品审批政策概述 被引量:2

Introduction of the American Examination and Approval Policies for Pediatric Drugs
下载PDF
导出
摘要 简要介绍美国儿科药品审批政策并进行深入分析,总结其成功经验,为建立适合我国的儿科药品审批政策提供参考。 This paper briefly introduced and analyzed the examination and approval policies of FDA for pediatric drugs. Their successful experiences were summarized and can be used as reference for the establishment of the policies adaptive to the situation of China for the examination and approval of pediatric drugs.
作者 成殷 邵蓉
出处 《中国执业药师》 CAS 2012年第5期43-46,共4页 China Licensed Pharmacist
关键词 儿科药品 审批政策 美国食品药品监督管理局 Pediatric Drug Examination and Approval Policy U.S. FDA
  • 相关文献

参考文献5

二级参考文献38

  • 1张蕾,王永铭,陈斌艳,沈刚.儿童药物不良反应研究[J].中国临床药理学杂志,1996,12(1):39-45. 被引量:44
  • 2李润标.儿科的不合理处方(附6417张处方分析)[J].广东药学院学报,1996,12(3):200-202. 被引量:2
  • 3Roberts R, Rodriguez W, Murphy D, et al. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies[J ] .JAMA, 2003, 290(7) :905.
  • 4Mathis L. Growth and Development of Pediatric Drug Development at the FDA [EB/OL]. http://www.fda. gov/oc/opt/presentations/drugdevelopment .ppt. 2006- 06.2008- 07.
  • 5FDA. The Pediatric Exclusivity Provision [EB/OL]. http://www, fda .gov/cder/pediatric/reportcong01. pdf. 2001 - 01. 2008 - 07.
  • 6FDA. Food and Drug Administration Amendments Act of 2007[ EB/OL ] . http ://frwebgate. access, gpo. gov/cgi - bin/getdoc .cgi? dbname = 110_cong_public_ laws&docid = f:pub1085.110. 2007- 09. 2008- 07.
  • 7FDA.Best Pharmaceuticals for Children Act [EB/OL]. http ://www. fda. gov/opacom/laws/pharmkids/contents .html. 2002 - 01. 2008 - 07.
  • 8FDA. Guidance for Industry - Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug, and Cosmetic Act [ EB/OL ] . http ://www. fda .gov/cber/gdlns/pedexc .htm. 2008 - 07.
  • 9FDA. Pediatric Research Equity Act of 2003 [ EB/OL ]. http://www. fda. gov/cder/pediatric/S - 650 - PREA. pdf. 2003. 2008-07.
  • 10FDA. Pediatric Exclusivity Statistics as of October 31, 2008[ EB/OL ] . http ://www. fda. gov/cder/pediatric/ wrstats, htm. 2008- 10. 2008- 10.

共引文献46

同被引文献16

  • 1刘昌庭.小儿生理特点及用药安全[J].中国现代药物应用,2007,1(11):103-104. 被引量:5
  • 2FDA. New Molecular Entity 2010 Statistics[EB/OL]. [2014-03-01] http ://www. fda. gov/downloads/drugs/developmentapprovalpro- cess/howdrugsaredevelopedandapproved/drugandbiologicapprov- alreports/ucm242695.pdf.
  • 3IMS. Top Corporation by Prescriptions Total RXin millions[EB/OL]. (2011-04-07)[2014-03-01]. http://www.imshealth.com/deployedfiles/Top-line%20Market % 20Data/2010 % 20Top-line % 20Market % 20Data/2010_Top_ Corporations_by_RX.pdf.
  • 4FDA. FactsaboutGenericDrugs[EB/OL].(2012-09-19)[2014-03-01]. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/Buyin- gUsingMedicineSafely/UnderstandingGenericDrugs/ucm 167991.htm.
  • 5Marlene E. Haffner, Janet Whitley, Marie Moses.Two decades of orphanproduct development[J]. NatureReviews Drug Discovery, 2002, 1( 10): 821-825.
  • 6FDA. Pediatric Exclusivity Granted[EB/OL].(2014-02-05) [2014- 03-01 ].http ://www. fda. gov/drugs/developmentapprovalprocess/ .htm.
  • 7IMS. Top 20 Global Therapeutic Classes, 2010, Total Audited Markets[EB/OL]. [2014-03-01]. http://www.ims.com.
  • 8FDA. FY 2011: performance report to the president and congress for the Prescription Drug User Fee Act[EB/OL].(2012-03-01) [2014- 03-01]. http://www.fda.gov/downloads/AboutFDA/ReportsManu- alsForms/Reports/UCM294101.pdf. UFA/.
  • 9FDA. Guidance for Industry 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day[EB/OL]. (2003-07) [2014- 03-01]. http://www.fda.gov/downloads/Drugs/GuidanceCompli- anceRegulatorylnformation/Guidances/UCM072851.pdf.
  • 10邵保国.小儿用药特点及用药中常见的问题和注意事项[J].现代中西医结合杂志,2009,18(8):951-953. 被引量:9

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部